GlassScriptPhysician profile
Dennis H Birenbaum
NPI 1538119045
$6,563.15
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,858 · 2020: $1,218 · 2021: $2,294 · 2022: $1,193.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,659.77 | 2019-2022 | |
| Incyte Corporation | $552.85 | 2019-2022 | |
| Pfizer INC. | $532.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $347.85 | 2019-2022 | |
| Eisai INC. | $343.49 | 2019-2022 | |
| Janssen Biotech, INC. | $327.49 | 2019-2022 | |
| Amgen INC. | $272.24 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $172.42 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $163.31 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.19 | 2019-2022 | |
| Kite Pharma, INC. | $130.32 | 2020-2022 | |
| Lexicon Pharmaceuticals, INC. | $117.72 | 2019-2020 | |
| Gilead Sciences, INC. | $112.08 | 2019-2022 | |
| Dova Pharmaceuticals | $110.90 | 2019-2021 | |
| Taiho Oncology, INC. | $107.75 | 2019-2022 |
Show all 50 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Birenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.